BioSpace News Archive

F2G Ltd today announced that it will present new clinical data in three oral presentations and two poster presentations at IDWeek 2022, to be held in Washington, D.C. from October 19-23, 2022.

OvaryIt, LLC announces their Notice of Award for a Phase 1 Small Business Innovation Research grant from the National Institutes of Health.

SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to accelerate a cure for facioscapulohumeral muscular dystrophy, announced an investment of US$10M million in Vita Therapeutics; a cell engineering company harnessing the power of genetics to develop novel cellular therapies to treat muscular dystrophies and solid tumours.

In addition to serving about half of hospitals and physicians and approximately 1 in 3 adults each year in the US, Quest Diagnostics has become a recognized thought leader and innovator in COVID-19 research and services.

The Society of Vascular and Interventional Neurology (SVIN) wants to create awareness around these events leading up to World Stroke Day on October 29 by challenging everyone to have #NoMercyOnStroke.

In an effort to create the pediatric research building of the future, Children’s Hospital of Philadelphia has joined forces with Gilbane Building Company, Pride Enterprises, and McKissack & McKissack to construct the Schuylkill Avenue Research Building.

NovelStem International Corp. (OTC Pink: NSTM), a development-stage company focused on the stem cell-based technology platform developed by 30%-owned, Israel-based NewStem Ltd., today announced that it has become an SEC-reporting company following the automatic effectiveness of its Form 10 registration statement filed August 2, 2022.

XBiotech announced the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer.

Some of the most influential international medical experts, researchers and scientific minds participated in the fifth Bioelectronic Medicine Summit, “Bioelectronic Medicine: Today’s Tools, Tomorrow’s Therapies,” hosted by The Feinstein Institutes for Medical Research.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”) today presented promising pharmacodynamic, tolerability and preliminary functional efficacy data from the first three participants dosed in CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease.